Boston Scientific Stock Underperforms Market Despite Strong Q2 Earnings
Boston Scientific Corporation (BSX) reported better-than-expected second-quarter earnings, but its stock continues to underperform both the S&P 500 and medical device sector ETFs. The company's shares have fallen over 51% year-to-date compared to a modest gain in the broader market index. Despite strong revenue growth of 7.5%, Boston Scientific lowered its full-year guidance for sales and earnings per share (EPS). Analysts remain optimistic, with a consensus rating of 'Strong Buy' based on recent upgrades. The company's strategic moves include a $1.5 billion investment in MiRus and late-stage clinical data releases that could drive future growth. Wall Street analysts have set an average price target for BSX at $70.33, representing a 52.8% upside from current levels.
Tickers: $BSX
Topics: Boston Scientific Q2 earnings report stock price underperformance